Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by SkywalkerofLukeon Apr 27, 2023 3:36pm

127 Views

Post# 35417803

CEO Interview

More than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have chronic kidney disease and as many as 9 in 10 adults do not know they have it.

AGN.c AGNPF is looking to address this market lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast) which they recently received a Notice of Allowance for from the US Patent and Trademark Office for patent.

AGN remaining consistent in their focus on discovering new therapeutic uses for drugs that are off patent and have a well-known safety history, but have never been marketed in the U.S. or Europe.

Here’s an interview with the CEO discussing the news.

https://www.youtube.com/watch?v=Ot-kWEvA3m0

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario